Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MNTA - Momenta Pharmaceuticals Inc.

Previous close
52.48
0   0%

Share volume: 0
Last Updated: Wed 30 Sep 2020 06:00:00 AM CEST
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
$52.48
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 50%
Dept financing 9%
Liquidity 17%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$52.48
P/E Ratio 
N/A
DAY RANGE
$52.48 - $52.48
EPS 
-$2.12
52 WEEK RANGE
$12.21 - $52.53
52 WEEK CHANGE
$318.50
MARKET CAP 
6.243 B
YIELD 
N/A
SHARES OUTSTANDING 
118.965 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$117,838,520
AVERAGE 10 VOLUME 
$2,684,930
AVERAGE 30 VOLUME 
$3,883,621
Company detail
CEO: Craig A. Wheeler
Region: US
Website: http://www.momentapharma.com
Employees: 118
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.

Recent news